Share This Article:

Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs

Full-Text HTML Download Download as PDF (Size:73KB) PP. 777-781
DOI: 10.4236/jct.2012.325097    4,401 Downloads   6,922 Views Citations

ABSTRACT

Triple negative breast cancer (TNBC) is characterized by a high sensitivity to antiblastic drugs and a high pathological complete remission rate after neoadjuvant therapy. In patients showing complete remission, the probability of developing metastatic disease would seem to be reduced. Nonetheless, this cancer has a high percentage of relapse. Anthracyclines, taxanes and platinum compounds are the most effective drugs for the treatment of TNBC. There is substantial evidence to support the efficacy of platinum-based chemotherapy, probably attributable to the mechanism of action of such drugs, which react with the DNA repair system. PARP inhibitors would also seem to be very interesting. Despite promising results, TNBC remains a disease with a poor prognosis due to the lack of targeted therapy. The discovery of new targets and new agents is thus a high priority issue for this type of breast cancer. In this respect, lipoplatin has been identified as a potentially interesting treatment option to evaluate in both neoadjuvant and advanced settings.

Cite this paper

M. Fantini, C. Santelmo, F. Drudi, C. Ridolfi, E. Barzotti, L. Gianni, V. Arcangeli, A. Affatato and A. Ravaioli, "Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs," Journal of Cancer Therapy, Vol. 3 No. 5A, 2012, pp. 777-781. doi: 10.4236/jct.2012.325097.

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.